tbuckley/cabot-search huggingface dataset:
Protective Effects of Ticagrelor on Myocardial Injury After Infarction
Authors: Gemma Vilahur, Manuel Gutiérrez, Laura Casani, Lourdes Varela, Antoni Capdevila, Guillem Pons-Lladó, Francesc Carreras, Leif Carlsson, Alberto Hidalgo, Lina Badimon
Journal: Circulation (2016)

The P2Y12 receptor antagonist ticagrelor has been shown to be clinically superior to clopidogrel. Although the underlying mechanisms remain elusive, ticagrelor may exert off-target effects through adenosine-related mechanisms. We aimed to investigate whether ticagrelor reduces myocardial injury to a greater extent than clopidogrel after myocardial infarction (MI) at a similar level of platelet inhibition and to determine the underlying mechanisms.Pigs received the following before MI induction: (1) placebo-control; (2) a loading dose of clopidogrel (600 mg); (3) a loading dose of ticagrelor (180 mg); or (4) a loading dose of ticagrelor followed by an adenosine A1/A2-receptor antagonist [8-(p-sulfophenyl)theophylline, 4 mg/kg intravenous] to determine the potential contribution of adenosine in ticagrelor-related cardioprotection. Animals received the corresponding maintenance doses of the antiplatelet agents during the following 24 hours and underwent 3T-cardiac MRI analysis. Platelet inhibition was monitored by ADP-induced platelet aggregation. In the myocardium, we assessed the expression and activation of proteins known to modulate edema formation, including aquaporin-4 and AMP-activated protein kinase and its downstream effectors CD36 and endothelial nitric oxide synthase and cyclooxygenase-2 activity.Clopidogrel and ticagrelor exerted a high and consistent antiplatelet effect (68.2% and 62.2% of platelet inhibition, respectively, on challenge with 20 μmol/L ADP) that persisted up to 24 hours post-MI (P<0.05). All groups showed comparable myocardial area-at-risk and cardiac worsening after MI induction. 3T-Cardiac MRI analysis revealed that clopidogrel- and ticagrelor-treated animals had a significantly smaller extent of MI than placebo-control animals (15.7 g left ventricle and 12.0 g left ventricle versus 22.8 g left ventricle, respectively). Yet, ticagrelor reduced infarct size to a significantly greater extent than clopidogrel (further 23.5% reduction; P=0.0026), an effect supported by troponin-I assessment and histopathologic analysis (P=0.0021). Furthermore, in comparison with clopidogrel, ticagrelor significantly diminished myocardial edema by 24.5% (P=0.004), which correlated with infarct mass (r=0.73; P<0.001). 8-(p-Sulfophenyl)theophylline administration abolished the cardioprotective effects of ticagrelor over clopidogrel. At a molecular level, aquaporin-4 expression decreased and the expression and activation of AMP-activated protein kinase signaling and cyclooxygenase-2 increased in the ischemic myocardium of ticagrelor- versus clopidogrel-treated animals (P<0.05). These protein changes were not observed in those animals administered the adenosine receptor blocker 8-(p-sulfophenyl)theophylline.Ticagrelor, beyond its antiplatelet efficacy, exerts cardioprotective effects by reducing necrotic injury and edema formation via adenosine-dependent mechanisms.
Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib
Authors: Anastasia Bykova, Adhamjon Abdullaev, Galina Gusarova, Ekaterina Chelysheva, Svetlana Treglazova, Svetlana Smirnova, Anna G. Turkina
Journal: Blood (2014)
Demographic Features of a Mixed Urban/Rural Adult Sickle Cell Population:Opportunities and Challenges for Improving Health Care
Authors: Amauri Bowman, Sydney Taylor, Pritam Bora, Hongyan Xu, Leigh Wells, Latanya Bowman, Nadine Barrett, Richard Lottenberg, E. Leila Jerome Clay, Betty Pace, Matthew Lyon, Robert Gibson, Abdullah Kutlar
Journal: Blood (2015)
The TNF −308G&gt;A Polymorphism Predicts Outcome of Patients with B-Cell Chronic Lymphocytic Leukemia In Relation to the IgVH Mutation Status
Authors: Ewa Lech-Maranda, Wojciech Mlynarski, Olga Grzybowska-Izydorczyk, Maciej Borowiec, Krystyna Wyka, Karolina Antosik, Agata Pastorczak, Barbara Cebula-Obrzut, Gabriela Klimkiewicz, Monika Wcislo, Grazyna Nowak, Hanna Makuch-Lasica, Miroslaw Majewski, Krzysztof Warzocha, Tadeusz Robak
Journal: Blood (2010)
CD4 and CD8 TCRαβ Cells Are selected On MHC Expressed On Thymocyte Precursors in OP9-DL1 Cultures.
Authors: Stefanie Van Coppernolle, Bart Vandekerckhove, Greet Verstichel, Imke Velghe, Tom Taghon, Georges Leclercq, Jean Plum, Tessa C. C. Kerre
Journal: Blood (2009)
Review of Matthew L. Baum, The Neuroethics of Biomarkers: What the Development of Bioprediction Means for Moral Responsibility, Justice, and the Nature of Mental Disorder1
Authors: Ryan H. Nelson
Journal: The American Journal of Bioethics (2016)

A long-running debate in the philosophy of medicine concerns the nature of disorder. Three prominent positions have emerged: Naturalists (see Boorse 1977) think that disorder should be understood i...
Prognostic Factors and Outcome of Human Herpesvirus 8 (KSHV/HHV-8)-Associated Primary Effusion Lymphoma (PEL) in Patients with AIDS.
Authors: Emmanuelle Boulanger, Laurence Gerard, Jean Gabarre, Jean-Michel Molina, Christophe Rapp, Jean-Francois Abino, Jacques Cadranel, Sylvie Chevret, Eric Oksenhendler
Journal: Blood (2004)
Annual Review of Biochemistry. Volume 20
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of NIH Consensus Criteria for Classification of Late Acute and Chronic Gvhd in Reduce Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).
Authors: Jifang Zhou, Sylvain Thepot, Aurrore Perrot, Marie Robin, Regis Peffault de Latour, Lionel Ades, Patricia Ribaud, Raphael Porcher, Gerard P Socie
Journal: Blood (2009)
A High Throughput Screen Identified Cyproheptadine That Decreases D-Type Cyclins, Arrests Cells in the G1 Phase, and Induces Apoptosis in Multiple Myeloma and Leukemia Cells.
Authors: Xinliang Mao, A. Keith Stewart, Rose Hurren, Marcela Gronda, Kyle Lee, Sue Chow, Shengben Liang, Suzanne Trudel, David W. Hedley, Aaron D. Schimmer
Journal: Blood (2007)
Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Other Clinical Features Including Age of the Patients
Authors: Dennis Dong Hwan Kim, Feras Alfraih, Tanya Adityan, Jeffrey H. Lipton
Journal: Blood (2015)
A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant.
Authors: Kathryn E. Webert, Richard J. Cook, Morris A. Blajchman, Stephen Couban, David M. Sutton, Jeffrey H. Lipton, Julie Carruthers, Joseph Brandwein, Nancy M. Heddle
Journal: Blood (2005)
A Pilot Study for Using 3′-Deoxy-3′-[18f]Fluorothymidine Positron Emission Tomography ([18F]FLT PET/CT) Imaging for Early Assessment of Response to Induction Chemotherapy in Acute Myeloid Leukemia (AML)
Authors: Mark B. Juckett, Matt Vanderhoek, Scott Perlman, Robert Nickles, Robert Jeraj
Journal: Blood (2008)
Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia.
Authors: Hai T. Ngo, Xavier Leleu, Anne-Sophie Moreau, Evdoxia Hatjiharissi, Xiaoying Jia, Garrett O’Sullivan, Judith Runnels, Rose Villarreal, Zachary Hunter, Steven Treon, Teru Hideshima, Kenneth Anderson, Irene Ghobrial
Journal: Blood (2006)
Induction of Megakaryocyte Polyploidization in Combination with JAK Inhibition As a Novel Therapeutic Strategy for Myeloproliferative Neoplasms
Authors: Qiang Jeremy Wen, Benjamin Goldenson, Sebastien Malinge, Priya Koppikar, Ross L Levine, Ayalew Tefferi, John Crispino
Journal: Blood (2011)
Bloodstream Infection after Reduced-Intensity Umbilical Cord Blood Transplantation Versus Other Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Shinsuke Takagi, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Daisuke Kato, Yoshiko Matsuhashi, Eiji Kusumi, Sachiko Seo, Naofumi Matsuno, Tomoko Matsumura, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shigesaburo Miyakoshi, Akiko Yoneyama, Michio Matsuzaki, Shuichi Taniguchi
Journal: Blood (2007)
Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not
Authors: Ravinder K Sandhu, Jack M. Lionberger, Megan Othus, John M. Pagel, Kathleen ShannonDorcy, Paul C. Hendrie, Stephen H. Petersdorf, Pamela S Becker, Frederick R. Appelbaum, Elihu H Estey
Journal: Blood (2011)
Phase II Study of Rituximab Combined with Cladribine and Mitoxantrone in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma
Authors: Shuichi Ota, Junji Tanaka, Masanobu Nakata, Kiyotoshi Imai, Masahiro Ogasawara, Yoshio Kiyama, Tatsuro Irie, Masanobu Morioka, Shintaro Umehara, Hiroshi Iwasaki, Koji Chiba, Yasutaka Kakinoki, Takashi Fukuhara, Masaharu Kasai, Masahiro Imamura
Journal: Blood (2008)
Clinical Scale Generation of Functional Human Natural Killer Cells From Umbilical Cord Blood CD34-Positive Cells for Immunotherapy.
Authors: Jan Spanholtz, Marleen Tordoir, Carel Trilsbeek, Jos Paardekooper, Diana Eissens, Arnold van der Meer, Irma Joosten, Frank Preijers, T. M. de Witte, Nicolaas Schaap, Harry Dolstra
Journal: Blood (2009)
Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.
Authors: Heather J. Sutherland, Joan Blade, Jesus San Miguel, Arnon Nagler, Pieter Sonneveld, Andrew Spencer, Tadeusz Robak, Wane O’Neal, Suneel D. Mundle, Sen H. Zhuang, Jean-Luc Harousseau, Robert Z. Orlowski
Journal: Blood (2007)
The Art of Breathing
Authors: Gary P. Anderson, Tom Kotsimbos
Journal: European Respiratory Journal (2016)

We think in images and when we reach the limits of our seeing our imagination takes over. Medicine and visual art have been inextricably linked since antiquity. Meticulously rendered images, and detailed polychromed models, have captured and codified the human body in its magnificence and rendered its manifold decrepitudes. Physicians need to parse visual appearances with the sophistication of connoisseurs every working day. And when great medical thinkers like Paul Erlich first imagined the "antibodies" and "receptors" that now underlay the science of almost our entire therapeutic pharmacopeia, that imagining was conveyed in beautiful conceptual diagrams that still astonish in the refinement of their artistry and inductive insight. The Art of Breathing is a conceptual meditation of art juxtaposed with notions of respiration and emotional thinking <http://ow.ly/i7D9305ikM1>
Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation,
Authors: Roland Fenk, Florian Neubauer, Ingmar Bruns, Christian Saure, Thomas Schroeder, Ulrich Germing, Norbert Gattermann, Rainer Haas, Guido Kobbe
Journal: Blood (2011)
Abstract 5507: Characterization of ADC bystander killing in admixed tumor model
Authors: Fu Li, Kim Kissler Emmerton, Mechthild Jonas, Xinqun Zhang, Che-Leung Law
Journal: Cancer Research (2015)

Abstract We have previously described an admixed tumor model, consisting of the CD30+ ALCL cell line Karpas 299 and CD30- Karpas-35R (SGN-35 resistant) cells, to study the phenomenon of ‘bystander killing’ of antigen negative tumor cells by antibody-drug conjugates (ADCs) in tumors with a heterogeneous target expression profile. Here we study the contribution of payload membrane permeability and target expression in bystander killing. We hypothesize that membrane permeability of payloads may impact bystander killing in addition to their intrinsic potency. Monomethyl auristatin E (MMAE)-based ADCs utilizing the cleavable linkers valine-citrulline (vc) or glucuronide (gluc) release the membrane permeable MMAE. As a result, antiCD30-vcMMAE and antiCD30-glucMMAE showed similar bystander killing in vivo. We then compared the more membrane permeable payloads, MMAE and pyrrolobenzodiazepine dimer (PBD), to those that are less permeable, monomethyl auristatin F (MMAF) and auristatin T (AT), as antiCD30 conjugates in this model. We found that antiCD30-AT and antiCD30-vcMMAF killed only CD30+ tumor cells in admixed tumors, while antiCD30-MMAE, antiCD30-GlucMMAE and antiCD30-PBD killed both CD30+ and CD30- cells. These results suggest that membrane permeability is one of the key factors determining in vivo bystander killing. To elucidate the role of antigen positive cells in bystander killing in this model, we varied the implant ratio of CD30+ cells and evaluated ADC activity in vivo. Flow cytometric analysis and CD30 immunohistochemistry confirmed a corresponding change of CD30+ cell percentage in the resulting admixed tumors (∼40%, 70%, or 80%). Treatment with ADCs in these tumors demonstrated that antiCD30-vcMMAE induced remissions in tumors with 70 or 80% CD30+ cells, whereas antiCD30-PBD produced remissions in all three admixed tumor ratios. Collectively, these data confirm that membrane permeable payloads can kill antigen negative cells in vivo. We hypothesize that the enhanced bystander killing by PBD-based ADCs may result from the intrinsic potency of the small molecule and/or membrane permeability. This information will be useful to consider when designing future ADCs. Citation Format: Fu Li, Kim Kissler Emmerton, Mechthild Jonas, Xinqun Zhang, Che-Leung Law. Characterization of ADC bystander killing in admixed tumor model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5507. doi:10.1158/1538-7445.AM2015-5507
Decreased Pulmonary Function in Asymptomatic Long Term Survivors After Busulfan-Based Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Authors: Annie L. Oh, Pritesh R. Patel, Santosh Saraf, Karen Sweiss, David Peace, John G. Quigley, Nadim Mahmud, Steven Dudek, Damiano Rondelli
Journal: Blood (2012)
ATIM-21. IMA950 PEPTIDE-BASED VACCINE ADJUVANTED WITH POLY-ICLC IN COMBINATION WITH STANDARD THERAPY IN NEWLY DIAGNOSED HLA-A2 GLIOBLASTOMA PATIENTS: PRELIMINARY RESULTS
Authors: Denis Migliorini, Valérie Dutoit
Journal: Neuro-Oncology (2016)

Phase I/II trial: HLA-A2 positive newly diagnosed GBM patients received after surgery, standard concurrent chemoradiation with temozolomide. In addition patients underwent 6 (before protocol amendment) or 4 (after protocol amendment) vaccinations of IMA-950 with poly ICLC (TLR3 agonist) once a week starting one week after the end of radiation, then 5 vaccinations once a month alternately with the 6 cycles of temozolomide. Primary endpoint was safety, secondary were OS, PFS at 6, 9 months, and immunological endpoints. 19 patients have been enrolled. The first 6 patients received the vaccine intradermally and the adjuvant intramuscularly (IM) in close vicinity and the site varied to stimulate the major draining lymph nodes. The preliminary analysis of vaccine-induced T cell responses didn’t show any induction of peptide-specific CD4 or CD8 T cells, leading to design a novel vaccination schedule/formulation. An amendment in the protocol incorporated the following changes: mixing vaccine/adjuvant before injection at one single site (thigh), decreasing the number of vaccinations during the induction phase, testing two different injection routes for the remaining 13 patients (subcutaneously or IM). Clinically, IMA-950 was well tolerated, the most common side effect was local inflammatory reaction at the injection site with mild fever. Some patients experienced cerebral edema, manageable with steroids. Among the 6 first patients, 2 showed disease progression, and median OS was 17.5 months (11–21). Patients under the amended protocol are still under therapy for 3 of them and 5 others finished the study protocol and are being followed without tumor recurrence. Analysis of vaccine-induced T cell responses in two of the 13 amended patients showed induction of both peptide-specific CD4 and CD8 T cells, suggesting those changes might lead to better immunization. IMA-950 is safe, preliminary mOS seems to be improved. Objective immune responses in two patients were observed.
Incidence of Adenovirus and BK Virus Reactivation and Diseases Following Reduced-Intensity Cord Blood Transplantation for Adult Patients.
Authors: Kazuya Ishiwata, Naoyuki Uchida, Hisashi Yamamoto, Shinsuke Takagi, Daisuke Kato, Sachiko Seo, Naofumi Matsuno, Kazuhiro Masuoka, Atsushi Wake, Shigesaburo Miyakoshi, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2007)
Recombinant Human Erythropoietin (rHuEpo) as an Anti-Myeloma Immunomodulatory Agent.
Authors: Sari Prutci-Sagiv, Odelia Katz, Lidor Yeyni, Alon Skaat, Eran Barzilay, Drorit Neumann, Moshe Mittelman
Journal: Blood (2004)
Long Term Results of Stanford V Regimen and Highly Active Antiretroviral Therapy (HAART) In 59 Patients (pts) with HD and HIV Infection (HD-HIV)
Authors: Michele Spina, Jean Gabarre, Salvatrice Mancuso, Alessandro Re, Clara Schiantarelli, Renato Talamini, Emanuela Vaccher, Umberto Tirelli
Journal: Blood (2010)
Stimulation of Anti-Tumor Immunity Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC-1 and Costimulatory Molecules (PANVAC-F).
Authors: Baldev Vasir, Corrine Lenahan, Jacalyn Rosenblatt, Adam Bissonnette, Zekui Wu, Donald Kufe, David Avigan
Journal: Blood (2006)
Sustained Molecular Responses with Interferon α2a Maintenance Therapy after Imatinib Plus IFN Induction Treatment for Chronic Phase Chronic Myelogenous Leukemia.
Authors: Andreas Hochhaus, Andreas Neubauer, Martin C. Mueller, Simone Napieralski, Philipp Erben, Tilman Bostel, Ruediger Hehlmann, Andreas Burchert
Journal: Blood (2007)
Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk
Authors: Djamel Aggoune, Nathalie Sorel, Sanaa El Marsafy, Marie Laure Bonnet, Denis Clay, Marie Claude Meunier, Karin Tarte, Olivier Herault, Jorge Domenech, Agnès Guerci, Jean-Claude Chomel, Ali G Turhan
Journal: Blood (2012)
Reply to M. Lambertini et al
Authors: Isabelle Demeestere, Pauline Brice, Fedro A. Peccatori, Alain Kentos, Jehan Dupuis, Pierre Zachee, Rene-Olivier Casasnovas, Eric Van Den Neste, Julie Dechene, Viviane De Maertelaer, Dominique Bron, Yvon Englert
Journal: Journal of Clinical Oncology (2017)
The Impact of Disease Status at Transplant and Time to First Relapse on Outcome in Children and Adolescents with Hodgkin’s Lymphoma Undergoing Autologous Stem Cell Transplantation.
Authors: Alexander Claviez, Hartmut Kabisch, Meinolf Suttorp, Christina Peters, Barbara Hero, Isabella Schiller, Wolfgang Doerffel, Norbert Schmitz, Felix Zintl
Journal: Blood (2004)
A Low Intensity Protocol of Fludarabine, Busulfan and Cyclophosphamide Reduces Toxicity without Compromising Engraftment in Children Undergoing Allogeneic Bone Marrow Transplantation for Beta Thalassaemia Major.
Authors: Biju George, Vikram Mathews, Auro Viswabandhya, Mammen Chandy, Alok Srivastava
Journal: Blood (2006)
Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.
Authors: Steven Horwitz, Craig Moskowitz, Tarun Kewalramani, Paul Hamlin, David Straus, Owen O’Connor, Ariela Noy, Carol Portlock, Stephen Nimer, M. Lia Palomba, Andrew Zelenetz
Journal: Blood (2005)
A Gene Expression Connectivity Map Identifies Rapamycin as a Glucocorticoid Resistance Reversal Agent in Lymphoblastic Leukemia.
Authors: Scott A. Armstrong, Guo Wei, Justin Lamb, Joseph Opferman, David Twomey, Ronald Stam, Monique den Boer, Stephen E. Sallan, Rob Pieters, Todd R. Golub
Journal: Blood (2005)
Single Nucleotide Polymorphism (SNP) Approach of Multiple Candidate Pathways Predicting the Risk of Acute / Chronic Graft-Versus-Host Disease or Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: Potential Involvement of Nuclear Factor Kappa-B (NFKB), Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-Beta (TGF-β) Pathway with Chronic Graft-Versus-Host Disease Graft-Versus-Host Disease.
Authors: Dong Hwan (Dennis) Kim, Jina Yun, Jee Hyun Kong, Chul Won Jung, Ahmed Galal, Vikas Gupta, John Kuruvilla, Hans A. Messner, Jeffrey H. Lipton
Journal: Blood (2009)
A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis
Authors: Bo Kyung A. Seong, Kelly E. Fathers, Robin Hallett, Christina K. Yung, Lincoln D. Stein, Samar Mouaaz, Lynn Kee, Cynthia E. Hawkins, Meredith S. Irwin, David R. Kaplan
Journal: Cancer Research (2016)

Metastatic relapse is the major cause of death in pediatric neuroblastoma, where there remains a lack of therapies to target this stage of disease. To understand the molecular mechanisms mediating neuroblastoma metastasis, we developed a mouse model using intracardiac injection and in vivo selection to isolate malignant cell subpopulations with a higher propensity for metastasis to bone and the central nervous system. Gene expression profiling revealed primary and metastatic cells as two distinct cell populations defined by differential expression of 412 genes and of multiple pathways, including CADM1, SPHK1, and YAP/TAZ, whose expression independently predicted survival. In the metastatic subpopulations, a gene signature was defined (MET-75) that predicted survival of neuroblastoma patients with metastatic disease. Mechanistic investigations demonstrated causal roles for CADM1, SPHK1, and YAP/TAZ in mediating metastatic phenotypes in vitro and in vivo Notably, pharmacologic targeting of SPHK1 or YAP/TAZ was sufficient to inhibit neuroblastoma metastasis in vivo Overall, we identify gene expression signatures and candidate therapeutics that could improve the treatment of metastatic neuroblastoma. Cancer Res; 77(3); 696-706. ©2017 AACR.
Appliance of the DNA-Micro Array Technique for the Identification of Patients with Thrombophilic Diathesis. I-Comparison to the Classic PCR Analysis.
Authors: Maria M.K.T. Tsaousidou, Fotis F.I.G. Girtovitis, Afroditi A.K. Boutou, Elefteria E.P. Pithara, Pantelis M.E.P. Makris
Journal: Blood (2004)
“Designer” Cells for Cellular Immunotherapy: Zinc Finger Nuclease (ZFN) Stimulated Targeted Recombination for the Simultaneous Disruption of the Endogenous Glucocorticoid Receptor and Site-Specific Addition of the IL13-Zetakine.
Authors: Andreas Reik, Michael C. Holmes, Fyodor D. Urnov, Yuanyue Zhou, Matthew Mendel, Pei-Qi Liu, Erica Moehle, Edward J. Rebar, Jeffrey C. Miller, Dale Ando, Philip D. Gregory, Michael Jensen
Journal: Blood (2006)